Sumitovant Biopharma completed the acquisition of the remaining shares in Myovant Sciences for $1.7bn.

Sumitovant Biopharma, a technology-driven biopharmaceutical company, completed the acquisition of the remaining shares in Myovant Sciences, a biopharmaceutical company that develops and commercializes new treatments for women’s diseases and endocrine disorders, for $1.7bn. "This transaction represents an industry-leading opportunity to combine unique expertise, platforms, and resources to successfully commercialize products in Myovant's program and to accelerate development of a robust pipeline addressing patient needs in women's health and prostate cancer. We look forward to harnessing the combined strength of our talented teams to bring needed therapies to patients sooner and are confident both Myovant and its employees will benefit from the greater resources Sumitovant can provide to further support business growth and career opportunities overall," Myrtle Potter, Sumitovant CEO.